Given that we previously reported that DLBCL patient samples [47], as well as cell lines in this current study (Figure 1B,F), typically overexpress more than one anti-apoptotic BCL2 family member, and in light of the low clinical efficacy of single-agent venetoclax in DLBCL [20], we assessed whether the addition of BCLX or MCL1 inhibitors to venetoclax was able to sensitize DLBCL cells to venetoclax. This evidence concerns the gene BCL2L1 and diffuse large B-cell lymphoma.